News Digest / Ticker: EXEL

Ticker: EXEL

07:14am, Monday, Oct 20, 2025

Exelixis Shares Drop Amid Mixed Outcomes from Late-Stage Cancer Trials

Exelixis shares slide over 9% following mixed results from late-stage trials for colorectal and neuroendocrine tumors, highlighting challenging paths in oncology drug development.

05:01pm, Monday, Jul 28, 2025

Exelixis Reports Q2 2025 Results: Revenue Drop Amid Strong Product Sales and Stock Buyback Program